Pitavastatin 4mg

DRUG4 trials

Sponsors

Kowa Research Institute, Inc., Korea University Anam Hospital, JW Pharmaceutical

Conditions

AnginaAtherosclerosisHypercholesterolemiaNeointimaSevere Renal Impairment

Phase 4

Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers

CompletedNCT01043094

Kowa Research Institute, Inc.Severe Renal Impairment

Start: 2009-12-31End: 2010-12-31Updated: 2012-08-13

Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis

CompletedNCT02545231

Korea University Anam HospitalAngina, Atherosclerosis, Neointima

Start: 2013-02-28End: 2020-08-31Updated: 2020-11-10

Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides

Active, not recruitingNCT07442630

JW PharmaceuticalHypercholesterolemia

Start: 2023-08-21End: 2026-11-30Updated: 2026-03-02

Unknown Phase

The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment

JW PharmaceuticalHypercholesterolemia

Start: 2018-07-01End: 2022-06-30Target: 905Updated: 2021-04-13

Related Papers

Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up

Cardiovascular Diabetology2019-11-2117 citations

Effects of lowest-dose vs. highest-dose pitavastatin on coronary neointimal hyperplasia at 12-month follow-up in type 2 diabetic patients with non-ST elevation acute coronary syndrome: an optical coherence tomography analysis.

2018-07-253 citations